Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBRX-042 in HPV-Associated Tumors
NCT05976828Phase 1Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Jun 2024
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBRX-042 in HPV-related carcinoma (3 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jun 2024; status: active, not recruiting.
02
Drugs
IBRX-042
03
Conditions
HPV-related carcinoma
Beyond the preview
Go deeper on NCT05976828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976828.